350 rub
Journal Technologies of Living Systems №9 for 2012 г.
Article in number:
Free light chains - biochemical markers of monoclonal gammapathies
Keywords: &#954 - and &#955 -free light chains blood serum monoclonal gammapathies
Authors:
N.V. Lyubimova, T.V. Ageeva, T.Yu. Kharitidy, A.N. Danilov, O.M. Votyakova
Abstract:
Serum κ- and λ-free light chains and its ratio were measured in 126 patients 23 - 80 years old with monoclonal gammapathies and 60 normal individuals 25 - 82 years old. The diagnosis were intact immunoglobulin multiple myeloma (IIMM) (n=87), Bence Jones myeloma (n=18), nonsecretory MM (n=7), plasmоcytoma (n=6) and monoclonal gammapathies of undetermined significance (MGUS) (n=8). The FLCs assay was performed using the FreeliteTM assay (The Binding Site Ltd, UK) on a Hitachi 911 automated nephelometer. sFLC levels were found to be high in most patients with IIMM, Bence Jones myeloma and plasmоcytoma. The diagnostic accuracy of FLC assay in serum by immunoturbidimetry method was 90,5 %. Combining sFLC testing with serum protein electrophoresis and immunofixation provides 98,8 % accuracy in the first-line diagnosis of monoclonal gammapathies. Our study demonstrated high diagnostic sensitivity and specificity for immunoturbidimetry method detection of FLC in serum of patients with monoclonal gammapathies.
Pages: 15-20
References
  1. Kuhnemund A., Liebisch P., Bauchmuller K. et al. «Light-chain escape-multiple myeloma» - an escape phenomenon from plateau phase: report of the largest patient series usinf LC-monitoring // J. Cancer Res. Clin. Oncol. 2009. V. 135. № 3. P. 477 - 484.
  2. Serum free light chain analysis / Eds. A.R. Bradwell. Birmingham. 2006. 312 р.
  3. Dispenzjeri A., Kyle R., Merlini G. et al.International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders // Leukemia. 2008. V. 23. № 2. P. 215 - 224.
  4. Bradwell A.R., Carr-Smith H.D., Mead G.P., Harvey T.C., Drayson M.T. Serum test for assessment of patient with Bence Jones Myeloma // Lancet. 2003. V. 361. № 9356. P. 489 - 491.
  5. Bradwell A.R. Serum free light chain measurement move to center stage // Clin. Chem. 2005. V. 51.P. 805 - 807.
  6. Bradwell A.R., Carr-Smith H.D., Mead G.P., Tang L.X., Showell P.J., Drayson M.T., Drew R. Highly sensitive, automated immunoassay for immunoglobulin free
    light chains in serum and urine // Clin. Chem. 2001. V. 47. № 4. P. 673 - 680.
  7. Nowrousian M.R., Brandhorst D., Sammet C., Kellert M., Daniels R., Schuett P. et al. Serum free light chain analysis and urine immunofixation electrophoresis in patients with multiple myeloma // Clin. Cancer Res. 2005. V. 11. № 24. P. 8706 - 8714.
  8. Katzmann J.A., Clark R.J., Abpaham R.S., Bryant S., Lymp J.F., Bradwell A.R., Kyle R.A. Serum reference intervals and diagnostic ranges for free kappa and free lambda immunoglobulin light chains: relative sensitivity for detection pf monoclonal light chains // Clin. Chem. 2002. V. 48. P. 1437 - 1444.
  9. Daval S., Tridon A., Mazeron N., Ristori J.M., Evrard B. Risk of antigen excess in serum free light measurements // Clin. Chem. 2007. V. 53. P. 1985-1986.
  10. Tate J.R., Mollee P., Dimeski G., Carter A.C., Gill D. Analytical performance of serum free light-chain assay during monitoring of patients with monoclonal light-chain diseases // Clin. Chem. Acta. 2007. V. 376.  P. 30 - 36.